Atea Pharmaceuticals Plans Mid-2026 C-BEYOND Readout, C-FORWARD Enrollment Completion and HEV Phase 1 Start
Atea Pharmaceuticals completed enrollment of over 880 patients in its C-BEYOND Phase 3 hepatitis C trial in December 2025 and expects topline results mid-2026, while C-FORWARD enrollment is set to finish mid-2026 with readouts around year-end. Preclinical data for AT-587 hepatitis E candidate support a Phase 1 start mid-2026.
1. Phase 3 C-BEYOND Trial Nears Readout
Atea completed enrollment of over 880 patients in its North American C-BEYOND trial in December 2025, comparing its bemnifosbuvir/ruzasvir regimen to sofosbuvir/velpatasvir. The company targets topline efficacy data mid-2026 measuring sustained virologic response 12 weeks post-treatment.
2. Phase 3 C-FORWARD Enrollment Progress
The C-FORWARD trial outside North America is on track to complete enrollment by mid-2026 and aims to report topline results around year-end 2026. Both trials assess HCV RNA below the lower limit of quantitation at 24 weeks from treatment start.
3. Phase 2 Data Highlight Differentiation
In the Phase 2 study, the eight-week bemnifosbuvir/ruzasvir regimen achieved 98% SVR12 in the adherent population and 95% in efficacy-evaluable patients. Data also demonstrated a high barrier to resistance, convenience with co-medications and minimal drug–drug interactions.
4. HEV Program Advances to Phase 1
Encouraging preclinical results for AT-587, targeting hepatitis E virus in immunocompromised individuals, support its potential as a first-in-class therapy. Atea plans to initiate a Phase 1 clinical trial for AT-587 in mid-2026 to address this unmet medical need.